Texas Capital Bancshares Inc. TX bought a new position in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,975 shares of the company’s stock, valued at approximately $332,000.

A number of other large investors have also recently bought and sold shares of the stock. City Holding Co. boosted its stake in Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares during the last quarter. Howe & Rusling Inc. boosted its stake in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the last quarter. TCI Wealth Advisors Inc. boosted its stake in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the last quarter. Archford Capital Strategies LLC boosted its stake in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the last quarter. Finally, Kernodle & Katon Asset Management Group LLC boosted its stake in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the last quarter. 11.16% of the stock is owned by institutional investors.

Novartis AG (NYSE:NVS) opened at 83.86 on Tuesday. The stock has a market cap of $196.47 billion, a PE ratio of 30.62 and a beta of 0.73. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The company’s 50 day moving average is $84.10 and its 200 day moving average is $78.88.

Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The firm had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. Novartis AG’s revenue for the quarter was down 1.8% on a year-over-year basis. On average, equities research analysts expect that Novartis AG will post $4.73 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/texas-capital-bancshares-inc-tx-buys-new-stake-in-novartis-ag-nvs/1488674.html.

A number of equities research analysts recently commented on the stock. UBS AG reissued a “neutral” rating on shares of Novartis AG in a research report on Tuesday, May 30th. Cowen and Company set a $90.00 price target on shares of Novartis AG and gave the stock a “hold” rating in a report on Wednesday, August 9th. BidaskClub cut shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Friday. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Thursday, June 8th. Finally, TheStreet raised shares of Novartis AG from a “c+” rating to a “b” rating in a report on Friday, June 2nd. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $83.56.

In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.01% of the stock is currently owned by corporate insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.